Cytos, Checkmate Pharma deal

Cytos granted Checkmate exclusive, worldwide rights to its platform technologies for virus-like particles (VLPs) and oligonucleotide synthesis, including CYT003. Checkmate plans to use the platform to develop oligonucleotide-based products in the field of immuno-oncology. Checkmate will rename CYT003 as CMP-001 and plans to advance the compound into a Phase Ib trial to treat solid tumors in early 2016.

In April 2014, Cytos discontinued a Phase IIb trial of CYT003, a virus-like particle (VLP) containing an oligonucleotide agonist of toll-like receptor 9 (TLR9), in severe allergic asthma ...